Mechanisms of Weight Loss in Patients Diagnosed With Achalasia

Sponsor
Vanderbilt University Medical Center (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT03063463
Collaborator
(none)
50
1
87.5
0.6

Study Details

Study Description

Brief Summary

Currently there are no existing data to determine why some achalasia patients lose weight while others do not. The purpose of this study is to gather data from patients diagnosed with achalasia to determine if differences may be identified between those who lose weight and those who do not that would help us better understand the mechanism of weight loss in this population.

Condition or Disease Intervention/Treatment Phase
  • Procedure: pneumatic dilation
  • Procedure: surgical myotomy

Detailed Description

Patients either diagnosed with or being evaluated for achalasia and scheduled for standard clinic visits with the principal investigator as part of their routine care will be considered for participation in this study. Blood work, vital signs, and 24-hour dietary recall will be collected over a period of one year. These data will lay the foundation for future scientific endeavors to : a) assess requirements for dietary and/or nutritional supplements; b) formulate an achalasia diet; c) develop clinical practice standards; and d) design an intervention study.

Study Design

Study Type:
Observational
Anticipated Enrollment :
50 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Mechanisms of Weight Loss in Patients Diagnosed With Achalasia: A Prospective Observational Study
Actual Study Start Date :
Feb 15, 2017
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Pneumatic Dilation

Subject with achalasia undergoing routine care EGD (Esophagogastroduodenoscopy) with pneumatic dilation

Procedure: pneumatic dilation
Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.

Surgical Myotomy

Subject with achalasia undergoing routine care EGD with surgical myotomy

Procedure: surgical myotomy
This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.

Outcome Measures

Primary Outcome Measures

  1. Body weight [One year]

    Currently there are no existing data to determine why some achalasia patients lose weight while others do not. The purpose of this study is to determine if differences may be identified between those who lose weight and those who do not. Body weight will be monitored at study visits throughout the study.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Subject is able to provide written informed consent to participate in the study before completing any study-related procedures

  2. Subject is male or female aged 18-75 years, inclusive at time of consent.

  3. Subject has a documented diagnosis of achalasia based on high resolution manometry and endoscopy report.

  4. Subject has been or will be scheduled to undergo either EGD with pneumatic dilation or surgical myotomy as routine care for treatment of achalasia.

  5. Subject is willing and has an understanding and ability to fully comply with study procedures and restrictions defined in this protocol.

Exclusion Criteria:
  1. Subject has any condition or abnormality, current or past that, in the opinion of the principal investigator, would compromise the safety of the subject or interfere with or complicate the assessment of signs or symptoms of achalasia. Such conditions may include psychiatric problems; neurologic deficits or disease; developmental delay; lung transplant; or previous gastroesophageal surgery.

  2. Subject has had previous pneumatic dilation of treatment of achalasia.

  3. Subject has had botulinum toxin (botox) injection for treatment of achalasia.

  4. Subject has a history or high risk of noncompliance with treatment or regular clinic visits.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Vanderbilt University Medical Center Nashville Tennessee United States 37212

Sponsors and Collaborators

  • Vanderbilt University Medical Center

Investigators

  • Principal Investigator: Michael Vaezi, MD,PhD, Vanderbilt University Medical Center

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Michael Vaezi, Principal Investigator, Vanderbilt University Medical Center
ClinicalTrials.gov Identifier:
NCT03063463
Other Study ID Numbers:
  • 161769
First Posted:
Feb 24, 2017
Last Update Posted:
May 5, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 5, 2022